242650US0CONT

TATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Wolf-Ruediger SCHAEBITZ, et al.

SERIAL NO: 10/659,295

September 11, 2003

FOR:

FILED:

METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOIETIC GROWTH FACTORS

GAU:

1614

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

\boxtimes	The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed
	references are attached, where required, as are either statements of relevancy or any readily available English
	translations of pertinent portions of any non-English language references.

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be
related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies
of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the
attached PTO form 1449.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

Each item of information contained in this information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of
this statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Daniel J. Pereira, Ph.D.

Registration No. 45,518

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Wolf-Ruediger SCHAEBITZ, et al.

SERIAL NO:

10/659,295

GAU:

1614

FILED:

September 11, 2003

FOR:

METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOIETIC GROWTH FACTORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

\boxtimes	The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed
	references are attached, where required, as are either statements of relevancy or any readily available English
	translations of pertinent portions of any non-English language references.

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be
related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies
of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the
attached PTO form 1449.

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

Each item of information contained in this information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of
this statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Daniel J. Pereira, Ph.D.

Registration No. 45,518

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03) FEB 2 5 2005

Form PTO 1449	Form PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRANSPORTED.		ATTY DOCKET NO.		SERIAL NO. 10/659,295			
(Modified)			242650US0CONT					
				APPLICANT				
LIST OF	REFE	RENCES CITED BY API	PLICANT	Wolf-Ruediger SCHAEBITZ, et	al.		·	
				FILING DATE		GROUP		
				September 11, 2003		1614		
	•			U.S. PATENT DOCUMENTS				
EXAMINER		DOCUMENT	DATE	NAME CLASS		SUB FILING DATE		
INITIAL		NUMBER	DATE	TANG	02.00	CLASS	IF A	PPROPRIATE
	AA	2002/151488	10/17/02	LAUFFENBURGER, et al.				
	AB							
	AC							
	AD							
	AE		<u> </u>					
	AF							
	AG							
	AH							
	Al							
	AJ							
	AK							
	AL							
	AM							
	AN	4						~
<u> </u>		·	FO	REIGN PATENT DOCUMENTS	.1.			
			1					
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO		
	AO	03/061685	07/31/03	WIPO				
	AP	1 374 898	01/02/02	EUROPE				
	AQ	02/099081	12/12/02	WIPO		1		
	AR							
	AS				-			
	AT							
	AU							
	AV							
<u> </u>	-	OTHER RE	FERENCES (Including Author, Title, Date, Pertinen	t Pages, et	tc.)	.	
			`				2G_CSF	:) 16
	AW SCHAEBITZ W. R. et al: "RECOMBINANT GRANULOCYTE-COLONY STIMULATING FACTOR (RG-CSF) IS NEUROPROTECTIVE FOLLOWING FOCAL TRANSIENT CEREBRAL ISCHEMIA AND EXCITOTOXITY" SOCIETY FOR NEUROSCIENCE, US, Vol. 27, No. Part 2, November 10, 2001, page 2027, AN76411, XP008009334, ISSN: 0190-5295 the whole document						SOCIETY FOR	
		KONISHI Y, et al.: "TF	ROPHIC EFFE	CT OF ERYTHROPOIETIN AND OTHER				
	AX			D AN IN VIVO.", BRAIN RESEARCH, Ap stract, Introduction, page 29, Discussion	•	•	, INO.S 1	-2, pages 29-35,
ļ-·-		HIERHOLZER, et al., "	ACTIVATION	OF STAT PROTEINS FOLLOWING ISC	HEMIA RE	PERFUSIO		
	AY			AND G-CSF MEDIATED PROFILE.", TR			ROCE	EDINGS, SEPT.
	1998, Vol. 30, No. 6, page 2647, XP001182894, ISSN: 0041-1345 the whole document TIAN SHIN-SHAY, et al.: "MULTIPLE SIGNALING PATHWAYS INDUCED							
	A ==	BY GRANULOCYTE COLONY-STIMULATING FACTOR INVOLVING ACTIVATION OF JAKS, STAT5, and/or STAT3 ARE REQUIRED FOR				Iditional References sheet(s) attached		
	AZ	REGULATION OF THE	REE DISTINCT	CLASSES OF IMMEDIATE EARLY				
[GENES" BLOOD, Vol. ISSN: 0006-4971 the		96, pages 4435-4444 XP001183387 nt				
Examiner					Date Considered			
				citation is in conformance with MPEP 60 with next communication to applicant.	09; Draw lin	ne through	citation	if not in

DOCKET NO. SERIAL NO. U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OF THE PA Form PTO 1449 (Modified) 242650US0CONT 10/659,295 **APPLICANT** LIST OF REFERENCES CITED BY APPLICANT Wolf-Ruediger SCHAEBITZ, et al. **FILING DATE GROUP** September 11, 2003 1614 **U.S. PATENT DOCUMENTS EXAMINER** DOCUMENT FILING DATE SUB **CLASS** DATE NAME **CLASS** IF APPROPRIATE INITIAL **NUMBER** BA BB BC BD BE BF BG BH ВΙ BJ BK BL BM BN FOREIGN PATENT DOCUMENTS DOCUMENT **TRANSLATION** DATE COUNTRY NUMBER YES NO BO BP BQ BR BS BT BU BV OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) WARD ALISTER, et al., "TYROSINE-DEPENDENT AND - INDEPENDENT MECHANISMS OF STAT3 ACTIVATION BY THE HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) RECEPTOR ARE DIFFERENTIALLY BW UTILIZED DEPENDING ON G-CSF CONCENTRATION", BLOOD, Vol. 93, No. 1, January 1, 1999 pages 113-124 XP001183113, ISSN: 0006-4971 the whole document SCHAEBITZ, et al. "NEUROPROTECTIVE EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR AFTER FOCAL CEREBRAL ISCHEMIA.", STROKE, Vol. 34, No. 3, March 2003, pages 745-751, XP002294803, ISSN: 0039-2399 BX the whole document BY Additional References sheet(s) attached BZ Examiner Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.